This connection has been exploited therapeutically with the introduction of the specific RANK-L-antibody Denosumab that prevents RANK-L-RANK-interaction in GC tumour of the bone and leads to a significant decline in GCs and bone resorption [91]. Here, TNFRSF11A is linked to neoplasm.